**Diets, Foods and Food Components Effect on Dyslipidemia**

Editors

**Federica Fogacci Arrigo F.G. Cicero Claudio Borghi**

MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin

*Editors* Federica Fogacci University of Bologna Italy

Arrigo F.G. Cicero University of Bologna Italy

Claudio Borghi University of Bologna Italy

*Editorial Office* MDPI St. Alban-Anlage 66 4052 Basel, Switzerland

This is a reprint of articles from the Special Issue published online in the open access journal *Nutrients* (ISSN 2072-6643) (available at: http://www.mdpi.com).

For citation purposes, cite each article independently as indicated on the article page online and as indicated below:

LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. *Journal Name* **Year**, *Volume Number*, Page Range.

**ISBN 978-3-0365-1238-9 (Hbk) ISBN 978-3-0365-1239-6 (PDF)**

© 2021 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications.

The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND.

### **Contents**



Reprinted from: *Nutrients* **2020**, *12*, 3127, doi:10.3390/nu12103127 .................. **261** vi

Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study)

**Arrigo F. G. Cicero, Cormac Kennedy, Tamara Knezevi´ ˇ c, Marilisa Bove, Coralie M. G. Georges, Agn ˙e Satrauskien ˙ ˇ e, Peter P. Toth and Federica Fogacci** Efficacy and Safety of Armolipid Plus®: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

Reprinted from: *Nutrients* **2021**, *13*, 638, doi:10.3390/nu13020638 ................... **271**

### **About the Editors**

**Federica Fogacci**, MDc is a Clinical Meta-analyst, a Research assistant affiliated with the University of Bologna (Italy) and an author of more than 80 articles focused on dyslipidaemia and its relationship with cardiovascular disease published in peer-reviewed and indexed international journals. She is a member of the Editorial Board of several International Journals concerned with population pharmacotherapy and investigation on atherosclerosis, its risk factors and clinical manifestations.

**Arrigo F.G. Cicero**, MD, PhD, is a Clinical Pharmacologist, a Professor of Human Nutrition at the University of Bologna (Italy), President of the Italian Nutraceutical Society and an author of more than 400 full papers published in international peer-reviewed indexed journals, mainly focused on nutraceuticals, dyslipidaemia, and other cardiovascular disease risk factors. He is a member of the Editorial Board of several International Journals concerned with population pharmacotherapy and investigation on atherosclerosis, its risk factors and clinical manifestations.

**Claudio Borghi**, MD, Inernist, is a Full professor of Internal Medicine, a PhD Director, and Emergency Medicine post-graduated school Director. He is author of more than 600 full papers published in international peer-reviewed indexed journals, mainly focused on cardiovascular disease risk factor, their interactions and management, Member of the Editorial Board of several International Journals concerned with population pharmacotherapy and investigation on atherosclerosis, its risk factors and clinical manifestations.

### *Editorial* **Diets, Foods and Food Components' Effect on Dyslipidemia**

**Federica Fogacci 1,2,3,\*, Claudio Borghi 1,2 and Arrigo F. G. Cicero 1,2,3**


Hypercholesterolemia is a well-known independent risk factor for cardiovascular disease and a recognized target of pharmacological therapeutic agents in both primary and secondary prevention [1]. There is increasing interest in the use of natural lipid-lowering compounds that may delay or circumvent drug therapy. These compounds could be included as part of a diet pattern, as single foods or as food components transformed into dietary supplements [2].

To date, there is a strong evidence showing that dietary factors are able to influence atherogenesis. In particular, the Mediterranean diet is particularly rich in active vegetable compounds, contributing to its positive effect on human health [3]. However, other active compounds could be isolated and concentrated from non-nutrient vegetable sources, such as medicinal plants [4]. Finally, natural dietary and non-dietary lipid-lowering compound could have pleiotropic effect on lipids and on other cardiovascular risk factors, for instance increasing the cholesterol resistance to oxidative stress, reducing microinflammation, improving the endothelial health, etc. [5].

Based on this background, the volume entitled "*Diets, Foods and Food Components' Effect on Dyslipidemia*" samples the contributions of a number of recognized experts in the field.

An interesting review summarizes the number of natural compounds reducing the plasma level of Proprotein convertase subtilisin/kexin type 9 (PCSK9), a key enzyme in the metabolism of LDL-cholesterol receptors on the liver cell surface [6].

Trautwein and McKay reviewed the effect of plant-based diet on dyslipidemia and cardiovascular risk [7]. Carresi et al. considered the potential effect of bergamot polyphenolic fraction on the prevention of metabolic syndrome [8] and Santos et al. critically appraised the efficacy of plant-derived omega-3 polyunsaturated fatty acids from foodstuffs and supplements upon lipid profile and several cardiometabolic markers [9].

A range of preclinical evidence highlights the antiobesity effect of *Chrysanthemum morifolium* [10], the antioxidant effect of red propolis [11], the cholesterol-lowering and hepatoprotective effects of black raspberry [12], the effect of blackcurrant in preventing dyslipidemia and hepatic steatosis [13], the antioxidant activity of polyphenon-60 from green tea in chitosan microspheres [14], and the combined effect of omega-3 fatty acids and glibenclamide on abnormal lipid profile, increased blood glucose and impaired liver and kidney functions [15].

New epidemiological evidence supports a link between different dietary patterns [16], charbohydrate intake [17], fructose intake [18], vitamin B12 serum levels [19] and lipid profile and other markers of cardiovascular disease risk. Findings from the randomized clinical trials included in the Special Issue support the use of new nutraceutical formulations with lipid-lowering effects. The BELT (Beta-glucan Effects on Lipid profile, glycemia and inTestinal health) study evaluated the medium-term effects of dietary supplementation with oat fibers in a sample of healthy subjects [20], and the NATCOL (NutrAceuTical COmbination on Low-density lipoprotein cholesterol) study tested the effect of dietary


**Citation:** Fogacci, F.; Borghi, C.; Cicero, A.F.G. Diets, Foods and Food Components' Effect on Dyslipidemia. *Nutrients* **2021**, *13*, 741. https:// doi.org/10.3390/nu13030741

Received: 22 February 2021 Accepted: 25 February 2021 Published: 26 February 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

supplementation with Levelip Duo® on low-density lipoprotein cholesterol concentrations and lipid profile in subjects with suboptimal blood cholesterol levels [21]. Finally, a systematic review and meta-analysis of randomized controlled clinical studies included in the Special Issue supports the use of Armolipid Plus® in clinical practice [22].

In this context, the volume is a source of new knowledge on the effect of diets, foods and food components on dyslipidemia.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

#### **References**


*Article*
